Medicamen Biotech Limited (MEDICAMEQ.BO)
INR 492.5
(6.9%)
INR 492.5
(6.9%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 593.75 Million INR | 31.78% |
| 2022 | 450.57 Million INR | 66.82% |
| 2021 | 270.09 Million INR | 419.04% |
| 2020 | 52.03 Million INR | -69.31% |
| 2019 | 169.57 Million INR | 11.12% |
| 2018 | 152.6 Million INR | 7.21% |
| 2017 | 142.34 Million INR | 3.22% |
| 2016 | 137.89 Million INR | 23.81% |
| 2015 | 111.37 Million INR | -17.28% |
| 2014 | 134.63 Million INR | 4.88% |
| 2013 | 128.37 Million INR | -15.12% |
| 2012 | 151.24 Million INR | 19.8% |
| 2011 | 126.24 Million INR | 1.39% |
| 2010 | 124.51 Million INR | 41.85% |
| 2009 | 87.77 Million INR | 19.02% |
| 2008 | 73.75 Million INR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q4 | 593.75 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 562.66 Million INR | 0.0% |
| 2023 FY | 593.75 Million INR | 31.78% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q2 | 288.48 Million INR | 0.0% |
| 2022 FY | 450.57 Million INR | 66.82% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 450.57 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q4 | 270.09 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 117.35 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 270.09 Million INR | 419.04% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 52.03 Million INR | -69.31% |
| 2020 Q4 | 52.03 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 78.68 Million INR | 0.0% |
| 2019 Q4 | 169.57 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 169.57 Million INR | 11.12% |
| 2019 Q2 | 128.12 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 132.1 Million INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 152.6 Million INR | 7.21% |
| 2018 Q4 | 152.6 Million INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q4 | 142.34 Million INR | 0.0% |
| 2017 FY | 142.34 Million INR | 3.22% |
| 2017 Q2 | 184.82 Million INR | 0.0% |
| 2016 Q2 | 111.76 Million INR | 0.0% |
| 2016 FY | 137.89 Million INR | 23.81% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q4 | 137.89 Million INR | 0.0% |
| 2015 Q2 | 142.56 Million INR | 0.0% |
| 2015 Q4 | 111.37 Million INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 111.37 Million INR | -17.28% |
| 2014 Q3 | - INR | -100.0% |
| 2014 FY | 134.63 Million INR | 4.88% |
| 2014 Q4 | 134.63 Million INR | 0.0% |
| 2014 Q2 | 96.6 Million INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q4 | 128.37 Million INR | 0.0% |
| 2013 FY | 128.37 Million INR | -15.12% |
| 2013 Q2 | 107.38 Million INR | 0.0% |
| 2012 Q2 | 137.18 Million INR | 0.0% |
| 2012 FY | 151.24 Million INR | 19.8% |
| 2012 Q4 | 151.24 Million INR | 0.0% |
| 2011 FY | 126.24 Million INR | 1.39% |
| 2011 Q4 | 126.24 Million INR | 0.0% |
| 2010 FY | 124.51 Million INR | 41.85% |
| 2009 FY | 87.77 Million INR | 19.02% |
| 2008 FY | 73.75 Million INR | 0.0% |
| 2008 Q4 | 73.75 Million INR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.43 Billion INR | 96.387% |
| Aurobindo Pharma Limited | 98.08 Billion INR | 99.395% |
| Glenmark Life Sciences Limited | 6.66 Billion INR | 91.093% |
| Granules India Limited | 13 Billion INR | 95.435% |
| Indoco Remedies Limited | 3.53 Billion INR | 83.183% |
| Achyut Healthcare Limited | 568 Thousand INR | -104433.803% |
| Ajanta Pharma Limited | 8.28 Billion INR | 92.832% |
| Alkem Laboratories Limited | 26.61 Billion INR | 97.769% |
| Alpa Laboratories Limited | 136.65 Million INR | -334.496% |
| Brooks Laboratories Limited | 96.1 Million INR | -517.797% |
| AstraZeneca Pharma India Limited | 2.27 Billion INR | 73.945% |
| Bajaj HealthCare Limited | 1.44 Billion INR | 58.778% |
| Bliss GVS Pharma Limited | 1.18 Billion INR | 49.872% |
| Dr. Reddy's Laboratories Limited | 63.55 Billion INR | 99.066% |
| Eris Lifesciences Limited | 1.89 Billion INR | 68.59% |
| FDC Limited | 3.88 Billion INR | 84.732% |
| Glenmark Pharmaceuticals Limited | 25.13 Billion INR | 97.637% |
| Gufic Biosciences Limited | 2 Billion INR | 70.384% |
| Ind-Swift Laboratories Limited | 104.57 Million INR | -467.765% |
| Ipca Laboratories Limited | 24.71 Billion INR | 97.597% |
| Jagsonpal Pharmaceuticals Limited | 149.97 Million INR | -295.914% |
| Krebs Biochemicals & Industries Limited | 97.96 Million INR | -506.092% |
| Lasa Supergenerics Limited | 190.43 Million INR | -211.789% |
| Laurus Labs Limited | 18.45 Billion INR | 96.783% |
| Lupin Limited | 49.53 Billion INR | 98.801% |
| Mankind Pharma Limited | 15.53 Billion INR | 96.178% |
| Medico Remedies Limited | 163.37 Million INR | -263.436% |
| Megasoft Limited | - INR | -Infinity% |
| NATCO Pharma Limited | 7 Billion INR | 91.524% |
| Piramal Pharma Limited | 21.75 Billion INR | 97.271% |
| RPG Life Sciences Limited | 1.01 Billion INR | 41.213% |
| Sigachi Industries Limited | 707.2 Million INR | 16.043% |
| Sun Pharmaceutical Industries Limited | 98.68 Billion INR | 99.398% |
| Suven Pharmaceuticals Limited | 2.31 Billion INR | 74.318% |
| Syncom Formulations (India) Limited | 210.81 Million INR | -181.646% |
| Unichem Laboratories Limited | 7.04 Billion INR | 91.574% |
| Wanbury Limited | 360.23 Million INR | -64.825% |
| Windlas Biotech Limited | 621.89 Million INR | 4.525% |
| ZIM Laboratories Limited | 812.62 Million INR | 26.934% |
| Zydus Lifesciences Limited | 34.41 Billion INR | 98.275% |
| Sun Pharma Advanced Research Company Limited | - INR | -Infinity% |
| Divi's Laboratories Limited | 31.84 Billion INR | 98.135% |
| Hester Biosciences Limited | 755.81 Million INR | 21.442% |
| Procter & Gamble Health Limited | 1.09 Billion INR | 45.582% |
| Amrutanjan Health Care Limited | 289.04 Million INR | -105.417% |
| Bal Pharma Limited | 878.11 Million INR | 32.383% |
| Strides Pharma Science Limited | 11.26 Billion INR | 94.728% |
| Venus Remedies Limited | 1.21 Billion INR | 51.208% |
| Aarti Pharmalabs Limited | 6.42 Billion INR | 90.764% |
| Nectar Lifesciences Limited | 7.09 Billion INR | 91.627% |
| Shilpa Medicare Limited | 3.44 Billion INR | 82.786% |
| Aarti Drugs Limited | 4.85 Billion INR | 87.78% |
| IOL Chemicals and Pharmaceuticals Limited | 4.24 Billion INR | 86.024% |
| Suven Life Sciences Limited | 7.08 Million INR | -8280.409% |
| Ind-Swift Limited | 640.91 Million INR | 7.359% |
| Valiant Laboratories Limited | 100.15 Million INR | -492.839% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.02 Billion INR | 88.184% |
| Solara Active Pharma Sciences Limited | 3.59 Billion INR | 83.493% |
| Themis Medicare Limited | 705.74 Million INR | 15.869% |
| Hikal Limited | 3.03 Billion INR | 80.451% |
| Torrent Pharmaceuticals Limited | 22.79 Billion INR | 97.395% |
| Sequent Scientific Limited | 3.46 Billion INR | 82.851% |
| Novartis India Limited | 448.6 Million INR | -32.357% |
| Wockhardt Limited | 6.4 Billion INR | 90.723% |
| Jubilant Pharmova Limited | 12.89 Billion INR | 95.396% |
| Biofil Chemicals and Pharmaceuticals Limited | 25.49 Million INR | -2228.713% |
| Neuland Laboratories Limited | 3.5 Billion INR | 83.056% |
| Morepen Laboratories Limited | 2.48 Billion INR | 76.116% |
| Kilitch Drugs (India) Limited | 39.88 Million INR | -1388.847% |
| Mangalam Drugs & Organics Limited | 1.23 Billion INR | 51.977% |